

Carcinogenesis vol.23 no.4 pp.595–598, 2002

CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka

Zeki Topcu1,6,7, Itsuo Chiba2, Masaki Fujiyada1,6, Toshikazu Shibata3, Noritaka Ariyoshi1, Hiroshi Yamazaki1, Figen Sevgican1,8, Malsantha Muthumala3, Hiroshi Kobayashi3, and Tetsuya Kamataki1,9

1Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, 2Department of Oral Patho-biological Science, Graduate School of Dental Medicine, Hokkaido University, Sapporo 060-0812, Japan, 3Department of Oral and Maxillofacial Surgery, Gifu University School of Medicine, Tsukasa-cho, Gifu, Japan, 4Oral and Maxillofacial Unit, General Hospital Kalutara, Sri Lanka, 5Sapporo Cancer Seminar Foundation, Sapporo, Japan and 6Organization for Pharmaceutical Safety and Research (OPSR), Tokyo, Japan
7Permanent address; Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, Izmir, 35100, Turkey
8Permanent address; Department of Endodontontology, Faculty of Dentistry, Ege University, Izmir, 35100, Turkey
9To whom correspondence and reprint requests should be addressed. Email: kamataki@pharm.hokudai.ac.jp

We investigated the relationship between inter-individual difference in CYP2A6 genotype and susceptibility to oral cancer among habitual betel quid chewers in a Sri Lanka population. A total of 286 subjects showing oral malignant or premalignant lesions and 135 control subjects with no lesions were analyzed. The frequency of homozygotes for CYP2A6*4C mutation, a gene deletion type of polymorphism, was significantly lower in the case subjects than the controls. The odds ratio (OR) of the group homozygous for the deletion was significantly lower and calculated to be 0.14 (95% CI: 0.03–0.72). In the allelic base analysis, there was also a significant decrease in the OR of the deletion allele. Our data suggest that deficient CYP2A6 activity due to genetic polymorphism reduces oral cancer risk in betel quid chewers.

Carcinoma of the oral cavity is one of the 10 most frequent malignant tumors worldwide with major predominance in south-east Asia and is a main problem in Sri Lanka (1). Oral squamous cell carcinoma and the most common oral premalignancies such as leukoplakia and oral submucous fibrosis appear to be related to the habit of betel quid (BQ) chewing in these countries, whereas in Western countries cigarette smoking and heavy alcohol consumption are the main causative agents. Areca nut (Areca catechu), a major component of BQ, contains certain alkaloids that give rise to nitrosamines, some of which such as N-nitrosoguvacoline, 3-(methylnitrosamino)propionitrile, 3-(methylnitrosamino)propionaldehyde and N-nitrosoguvacine, are shown to be carcinogenic (2). These BQ-specific nitrosamines may act as an adjunct to tobacco-specific nitrosamines that are strongly implicated as an etiologic factor for leukoplakia and oral submucous fibrosis. Metabolic activation of several nitrosamines was reported to be catalyzed by cytochrome P450 enzymes (CYPs), large multi-gene family enzymes important in phase I metabolic activation reactions (3). Furthermore, reactive oxygen species are generated in the oral cavity during BQ chewing due to the addition of slaked lime [Ca(OH)2] into BQ (4).

In Sri Lanka, the predominant habit is chewing BQ with tobacco. Although the influence of other factors such as nutritional conditions is important in the etiology of oral cancer, there is a wide inter-individual difference in the susceptibility to chemical carcinogens. Therefore, the known evidence for relevance of tobacco-specific nitrosamines to the oral cancer and inter-individual difference in the susceptibility to chemical carcinogens due to genetic polymorphism in the xenobiotic metabolizing enzymes may apply to some extent to chewers of BQ.

Among xenobiotic metabolizing enzymes, the CYP2A family is characteristic of its catalytic properties to nitrosamines (5). In addition, previous studies in our laboratory reported a novel deletion-type mutant of the CYP2A6 gene, CYP2A6*4C, as one of the major polymorphic genes in Japanese lacking CYP2A6 activity (6–8). The CYP2A6 gene deletion due to genetic polymorphism reduced lung cancer risk among tobacco smokers in a Japanese population (9). At present, we account for this fact by speculating that the subjects possessing CYP2A6*4C might not activate nitrosamines contained in tobacco smoke. Since the presence of the variant gene seems to reduce the activity of xenobiotics, it is possible that the polymorphism of CYP2A6 could also reduce the metabolic activation of BQ-derived carcinogens. In this study, we intended to clarify whether CYP2A6 genetic polymorphism, including the gene deletion, could be related to individual susceptibility to oral cancer in habitual BQ chewers in a Sri Lanka population. Because of the known involvement of Phase II enzymes in detoxification of reactive oxygen species, genotyping was extended to cover identification of glutathione-S-transferase µ class isozyme (GSTM1) in the same subjects.

All the subjects in this study were BQ chewers from Sri Lanka with or without smoking habit. Case and control groups were comparable to each other in terms of number of quids chewed per day (~5.5 betel/day). The control group consisted of subjects who visited a hospital for clinical reasons other than oral cancer. The ages shown as means SD of the patients with oral malignancies or premalignancies (246 males and 40 females) and the controls without any lesions (91 males and 44 females) were 52.6 ± 10.0 years (range, 40–82) and 52.6 ± 9.0 years (range, 40–85), respectively. Blood samples were obtained from the subjects with informed consent. Genomic DNA was isolated from peripheral blood by using Nucleic Acid Isolation System NA-3000 (Kurabo, Tokyo, Japan). The ethics committee of Hokkaido University, Sapporo, Japan and Peradeniya University ethical committee of Sri Lanka Dental Hospital approved this study.

Abbreviations: BQ, betel quid; CYPs, cytochrome P450 enzymes; GSTM1, glutathione-S-transferase µ class isozyme; PCR, polymerase chain reaction.
Table I. Distribution of CYP2A6 genotypes in controls and patients with oral lesions

<table>
<thead>
<tr>
<th>CYP2A6</th>
<th>Control (%)</th>
<th>Case (%)</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>*1A/*1A</td>
<td>49 (36.3)</td>
<td>116 (40.6)</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>*1A/*1B</td>
<td>53 (39.3)</td>
<td>118 (41.3)</td>
<td>0.94</td>
<td>0.59–1.50</td>
</tr>
<tr>
<td>*1B/*1B</td>
<td>13 (9.6)</td>
<td>38 (13.3)</td>
<td>1.23</td>
<td>0.61–2.52</td>
</tr>
<tr>
<td>*1A/*4C</td>
<td>8 (5.9)</td>
<td>9 (3.1)</td>
<td>0.48</td>
<td>0.17–1.30</td>
</tr>
<tr>
<td>*1B/*4C</td>
<td>6 (4.4)</td>
<td>3 (1.0)</td>
<td>0.21</td>
<td>0.05–0.88</td>
</tr>
<tr>
<td>*4C/*4C</td>
<td>6 (4.4)</td>
<td>2 (0.7)</td>
<td>0.14</td>
<td>0.03–0.72</td>
</tr>
<tr>
<td>Total</td>
<td>135</td>
<td>286</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*1A, wild type; *1B, conversion type; *4C, whole deletion type. Significant association between CYP2A6 genotypes and oral cancer risk is shown as χ² value 15.00, P=0.0104.

Table II. Allele frequency of CYP2A6 in controls and patients with oral lesions

<table>
<thead>
<tr>
<th>CYP2A6</th>
<th>Control (%)</th>
<th>Case (%)</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>*1A</td>
<td>159 (58.9)</td>
<td>359 (62.8)</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>*1B</td>
<td>85 (31.5)</td>
<td>197 (34.4)</td>
<td>1.03</td>
<td>0.75–1.41</td>
</tr>
<tr>
<td>*4C</td>
<td>26 (9.6)</td>
<td>16 (2.8)</td>
<td>0.27</td>
<td>0.14–0.52</td>
</tr>
<tr>
<td>Total</td>
<td>270</td>
<td>572</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*1A, wild type; *1B, conversion type; *4C, whole deletion type. Significant association in distribution of the three alleles between case and control subjects is shown as χ² value 18.09, P=0.0001.

The DNA samples were subjected to polymerase chain reaction (PCR) amplification for CYP2A6 and GSTM1 analyses. CYP2A6 genes were analyzed for the wild type (CYP2A6*1A), the deletion type (CYP2A6*4C) and the other type of mutant designated as conversion-type (CYP2A6*1B) by the methods developed in our laboratory (10). Briefly, a region ranging from the exon 8 of the CYP2A7 or CYP2A6 gene to a 3' untranslated region in the exon 9 of the CYP2A6 gene was amplified. The amplified DNA samples were treated with two restriction enzymes, AccII and EcoRI. GSTM1 amplification was carried out as described by Nair et al. (4). The co-amplification of an albumin gene fragment served as an internal positive control for PCR-amplification in determination of the homozygous null polymorphism of GSTM1.

To determine an association between CYP2A6 genetic polymorphism and oral cancer risk, the significance of the difference in the case-control distribution was calculated by χ² tests. Odds ratios were calculated by the statistical package StatView (ver. 4.5) (SAS Institute, Cary, NC, USA).

The genotyping method developed in our laboratory allows us to distinguish CYP2A6*4C (6–8), and CYP2A6*1B, (10) from CYP2A6*/1A. The prevalence of the CYP2A6 genotypes in patients with oral lesions of various classes (15 oral squamous cell carcinoma, 62 oral submucous fibrosis and 209 leukoplakia) and control subjects among BQ chewers is summarized in Table I. The individual distribution of six genotypes in Sri Lanka was significantly different from Japanese (χ²=34.90, P<0.0001) (9) and Korean (χ²=17.17, P=0.0042) (11) populations.

The χ² test indicated a significant difference in the distribution of six genotypes between the case and control groups (χ²=15.00, P=0.0104) (Table I). Prevalence of CYP2A6*/1A/*1A genotype was not significantly higher in the case group (40.6%) than in the controls (36.3%). The presence of homozygous deletion genotype (CYP2A6*4C/*4C) was seen in six control subjects (4.4%). A comparison with the patient group (0.7%) showed that this genotype was significantly more frequent in the control group, suggesting that there was a relationship between genetic polymorphism of CYP2A6 and oral cancer risk. The odds ratio (OR) calculated for the subjects harboring CYP2A6*4C/*4C was 0.14 (95% confidence intervals, 0.03–0.72), conferring on an individual having CYP2A6*4C/*4C genotype around seven times lower risk for the development of oral cancer than that of an individual with CYP2A6*/1A/*1A.

The significant association between the CYP2A6 genetic polymorphism and oral cancer risk was also found in allele-based analysis. Table II shows the frequencies of three allelic variants of the CYP2A6 gene in the subjects with oral pre-malignant lesions and controls. A significant difference in the distribution (χ²=18.09, P=0.0001) strengthened the role of CYP2A6 activity in oral carcinogenesis. We also analyzed 25 BQ-chewing subjects diagnosed as lichen planus lesion in our study. Lichen planus is an inflammatory lesion with hyperkeratosis characterized by pearly white papulaes (1). This condition has a high prevalence among BQ chewers and is currently considered as a ‘probable precancerous’ condition. However, there was no significance in the distribution of CYP2A6 genotypes in the subjects with lichen planus when compared to either the case (χ²=0.98, P=0.9639) or the control groups (χ²=3.30, P=0.0654) (data not shown). A larger sample size for this particular disease is needed for comparison of CYP2A6 genotypic distribution patterns.

All the subjects in this study were habitual BQ chewers. In addition to BQ chewing, numbers of subjects with the habits of cigarette smoking in case and control groups were 195 (68.2%) and 61 (45.2%), respectively. When we compared the subjects on the basis of their habits, significant association was more relevant in the habitual BQ chewers than in the subjects with both BQ chewing and cigarette smoking habits in either genotypic (χ²=13.38, P=0.0201 vs. χ²=6.24, P=0.2839) or allelic (χ²=8.35, P=0.0154 vs. χ²=7.04, P=0.0296) analyses (data not shown). However, this issue is further complicated because of the way the BQ is practiced in the subjects covered in our study. In Sri Lanka, like some other south-east Asian countries, BQ preparations also contain tobacco to some extent. Therefore, it was not possible to make a clear estimation on the individual contributions of these two habits. No attempt was made to approximate the total amount or lifetime chewing, smoking or alcohol consumption, as these are well-established lifestyle risk factors for oral carcinoma (12).

GSTM1 null genotype is ascribed to a homozygous deletion of the gene GSTT1. This genotype has been shown to predispose to oral cancer in some (4, 13) but not in all studies (14, 15). A study by Nair et al. demonstrated that the homozygous deletion of GSTM1 null genotype increased the risk for leukoplakia in betel/tobacco chewers in an Indian ethnic population (4), while Tanimoto et al. (15) reported that the prevalence of the null genotypes of GSTM1, alone, was not statistically significant between the patients who suffered from oral squamous cell carcinoma and the controls. We also analyzed the distribution of GSTM1 wild type (GSTM1w) and the null genotype among the same Sri Lanka subjects employed for the analysis of CYP2A6 genotypes. The GSTM1 assay we used was based on PCR to determine the presence or
absence of the gene without further description of GSTM1w subjects as homozygotes or heterozygotes (4). The frequency of GSTM1 null genotype in subjects with oral lesions did not differ significantly from the control (χ² = 2.44, P = 0.1182) (Table III). However, when the genotypes of CYP2A6 and GSTM1 were combined, the prevalence of CYP2A6 deletion allele in GSTM1w and the null genotypes was statistically significant between the case and control subjects (χ² = 8.52, P = 0.0141 and χ² = 12.67, P = 0.0018 in the GSTM1w and the null genotypes, respectively) (Table IV). The null genotype of GSTM1 was more frequently found in cases with the susceptible genotype of CYP2A6 than among controls. Confirming risk according to the GSTM1 genotype in the development of oral cancer needs to be analyzed with a larger population.

To our knowledge, two reports (16, 17) have appeared on the relationship between the genetic polymorphism of CYP2A6 gene and the lung cancer risk after we reported the close relationship (9). One paper showed negative results (16), and the other no conclusive results (17). The two papers showing rather contradictory results seem to be caused by two factors: One is by an unusual low frequency of CYP2A6*4C in Caucasians was about one-fifth that seen in a Japanese population (10). Thus, to reproduce our results, the study may require a total of 421 subjects in Sri Lanka were employed in this study. Another possibility to explain the apparent discrepancy between our previous results and results reported by other laboratory is ethnic differences. However, the results shown in this paper clearly indicate that the low risk was also seen in a Sri Lankan population, indicating that there are no apparent ethnic differences in the effects of genetic polymorphism of CYP2A6 gene on the risk of cancer.

In conclusion, this is the first report on the prevalence of the CYP2A6 genotypes in habitual BQ-chewers. Our results based on a case-control study suggest that the CYP2A6 genetic polymorphism has an impact on susceptibility to oral cancer. While there is no current evidence that the incidence of GSTM1 null alleles predominates in case subjects, the significance of homozygous CYP2A6*4C prevalence with respect to GSTM1 genotype is also noteworthy as an additional factor in oral cancer risk. The lesser risk of oral cancer in subjects with the CYP2A6*4C/4C genotype may be explained by the fact that individuals with this genotype are incapable of bioactivating BQ-specific procarcinogens to carcinogens. Accumulation of such information will be helpful in identification of high-risk individuals and in developing therapeutic strategies by both reducing the intake of carcinogenic substances and providing novel approaches targeting CYP2A6 for oral cancer. Inhibition of the activity of CYP2A6 and/or mimicking the decreased activity variants may produce the same benefits that are imparted by the deletion alleles. Studies on the expression of CYP2A6 in oral tissues and histopathological examination on biopsy specimens are currently in progress.

**References**


heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics, 10, 687–693.

Received November 20, 2001; revised January 7, 2002; accepted January 12, 2002